Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 3, 2006, Pages 204-211

  Haupt, Sue ^a   Zioni, Tamar ^a   Gati, Irith ^a   Kleinstern, Jackie ^a   Rubinstein, Abraham ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Celecoxib; Chitosan; Guar gum; HT 29 cell line; Local delivery; Mucoadhesion; Rat

Indexed keywords

BUFFER; CELECOXIB; CHITOSAN; GUAR GUM; LACTATE DEHYDROGENASE; POLYSACCHARIDE;

ADENOMATOUS POLYP; ADHESION; ADJUVANT CHEMOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADABILITY; CANCER CELL CULTURE; CECUM; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; EPITHELIUM; FAMILIAL POLYPOSIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; INTESTINE PERFUSION; LARGE INTESTINE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADHESIVENESS; ANIMALS; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FECES; GALACTANS; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; INTESTINAL MUCOSA; INTESTINES; MALE; MANNANS; PARTICLE SIZE; PLANT GUMS; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SULFONAMIDES;

EID: 33646802666     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.02.001     Document Type: Article

References (20)

1. Azab A.K., Srebnik M., Doviner V., and Rubinstein A. Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationized acrylamide copolymers. J. Contr. Rel. 106 (2005) 14-25
2. Ch'ng H.S., Park H., Kelly P., and Robinson J.R. Bioadhesive polymers as platforms for oral controlled drug delivery. II. Synthesis and evaluation of some swelling, water-insoluble bioadhesive polymers. J. Pharm. Sci. 74 (1985) 399-405
3. Fitzgerald G.A. Coxibs and cardiovascular disease. N. Engl. J. Med. 351 (2004) 1709-1711
4. Gill S., and Sinicrope F.A. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?. Semin. Oncol. 32 (2005) 24-34
5. Gliko-Kabir I., Yagen B., Baluom M., and Rubinstein A. Phosphated crosslinked guar for colon-specific drug delivery. II. In vitro and in vivo evaluation. J. Contr. Rel. 63 (2000) 129-134
6. Guirguis M.S., Sattari S., and Jamali F. Pharmacokinetics of celecoxib in the presence and absence of interferon induced acute inflammation in the rat: application of a novel HPLC assay. J. Pharm. Pharm. Sci. 4 (2001) 1-6
7. Haupt, S., Kleinstern, J., Haupt, Y., Rubinstein, A., 2006. Celecoxib can induce cell death independently of COX-2, p53, Mdm2, C-Abl and ROS. Anti-Cancer Drugs (in press).
8. Hsi L.C., Baek S.J., and Eling T.E. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp. Cell. Res. 256 (2000) 563-570
9. Juni P., Rutjes A.W., and Dieppe P.A. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?. BMJ 324 (2002) 1287-1288
10. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
11. Phillips R.K., Wallace M.H., Lynch P.M., Hawk E., Gordon G.B., Saunders B.P., Wakabayashi N., Shen Y., Zimmerman S., Godio L., Rodrigues-Bigas M., Su L.K., Sherman J., Kelloff G., Levin B., and Steinbach G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50 (2002) 857-860
12. Reddy B.S., Hirose Y., Lubet R., Steele V., Kelloff G., Paulson S., Seibert K., and Rao C.V. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 60 (2000) 293-297
13. Roh J.L., Sung M.W., Park S.W., Heo D.S., Lee D.W., and Kim K.H. Celecoxib can prevent tumor growth and distant metastasis in postoperative setting. Cancer Res. 64 (2004) 3230-3235
14. Rubinstein A., Nakar D., and Sintov A. Chondroitin sulfate: a potential biodegradable carrier for colon-specific drug delivery. Int. J. Pharm. 84 (1992) 141-150
15. Rubinstein A., and Tirosh B. Mucus gel thickness and turnover in the gastrointestinal tract of the rat, responses to cholinergic stimulus and implication for mucoadhesion. Pharm. Res. 11 (1994) 794-799
16. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
17. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342 (2000) 1946-1952
18. Wei D., Wang L., He Y., Xiong H.Q., Abbruzzese J.L., and Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res. 64 (2004) 2030-2038
19. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., and Dubois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045-6051
20. Xu J.M., Song S.T., Tang Z.M., Liu X.Q., Jiang Z.F., Zhou L., Li Y.B., and Huang Y. Evaluation of in vitro chemosensitivity of antitumor drugs using the MTT assay in fresh human breast cancer. Breast Cancer Res. Treat. 49 (1998) 251-259